



**HD** (AEPRR) Prima Biomed Ltd: Proposed Acquisition of Immutep

**WC** 267 words

**PD** 2 October 2014

**SN** Ralph Wragg Australian Business News

**SC** AAPRAW

**LA** English

**CY** Copyright 2014 RWE AUSTRALIAN BUSINESS NEWS PTY LTD. All Rights Reserved.

**LP**

Sydney - Thursday - October 02 (RWE) - Prima Biomed Ltd (ASX: PRR) announces that it has reached an agreement to acquire Immutep SA, a late stage privately owned biopharmaceutical company in the rapidly growing field of immuno-oncology.

Prima will pay consideration of up to approximately US\$28 M through a combination of cash, shares and warrants subject to the achievement of certain performance milestones.

**TD**

The transaction is to be funded via an investment agreement with Bergen Global Opportunity Fund, LP ("Bergen").

Immutep has been developing a number of complementary types of cancer immunotherapies based on its patented Lymphocyte Activation Gene 3 (LAG-3) technology.

Its lead product IMP321 has been tested in various clinical trials to date, both alone and in combination with other therapies.

Immutep holds the world-wide rights (ex China and Taiwan) to commercialise IMP321.

This includes trials in chemo-immunotherapy, a combination of immunotherapy and chemotherapy which significantly enhances patients' immune response to cancers.

Lucy Turnbull, Chair of Prima BioMed, said: "This is the most significant announcement in Prima's history.

It is the result of a long and diligent search process led by new Chief Executive Marc Voigt as part of our business development program.

It considerably strengthens our position in immuno-oncology, which is forecast to grow to a US\$35B industry by 20231.

"It significantly expands our clinical development product portfolio to other categories of immunotherapies beyond cancer vaccines, which includes our current lead product CVac.

It also provides us with partnerships with several of the world's largest pharmaceutical companies," she said.

**CO** primin : Prima Biomed Ltd

**IN** ibioph : Biopharmaceuticals | i2569 : Biotechnology | i257 : Pharmaceuticals | i951 : Health Care/Life Sciences | idrugty : Drugs/Medication

**NS** cacqu : Acquisitions | c18 : Ownership Changes | c181 : Acquisitions/Mergers/Takeovers | cactio : Corporate Actions | ccat : Corporate/Industrial News | ncat : Content Types | nfact : Factiva Filters | nfcpin : C&E Industry News Filter

**RE** austr : Australia | apacz : Asia Pacific | ausnz : Australia/Oceania

**PUB** RWE Australian Business News Pty Ltd

**AN** Document AAPRAW0020141002eaa20002x